Literature DB >> 18279069

Current concepts in malignant pleural mesothelioma.

Andrew J Kaufman1, Harvey I Pass.   

Abstract

Malignant pleural mesothelioma (MPM) is a rare but lethal cancer associated with asbestos exposure. Worldwide, the incidence of MPM is expected to increase over the next 20 years. The molecular and genetic profiling of MPM tumors and patients, and improved understanding of the pathogenesis of MPM may lead to novel diagnostic, preventative and therapeutic strategies. Treatment options for MPM remain limited and no consensus exists at this time. Multimodality therapy that combines surgery, chemotherapy and radiation offers the best chance for long-term survival in select patients.

Entities:  

Mesh：

Year:  2008        PMID： 18279069     DOI： 10.1586/14737140.8.2.293

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


  15 in total

1.  Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients.

Authors:  Emin Tamer Elkiran; Mehmet Ali Kaplan; Alper Sevinc; Sercan Aksoy; Umut Demirci; Mesut Seker; Hakan Harputluoglu; Nuriye Yildirim Ozdemir; Feridun Isik; Arife Ulas; Mevlude Inanc; Ulku Yalcintas Arslan; Gamze Gokoz Dogu; Abdurrahman Isikdogan; Suleyman Buyukberber
Journal:  Med Oncol       Date:  2012-06-22       Impact factor: 3.064

Review 2.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 3.  Role of microRNAs in malignant mesothelioma.

Authors:  A Truini; S Coco; A Alama; C Genova; C Sini; M G Dal Bello; G Barletta; E Rijavec; G Burrafato; F Boccardo; F Grossi
Journal:  Cell Mol Life Sci       Date:  2014-02-23       Impact factor: 9.261

4.  miR-1 induces growth arrest and apoptosis in malignant mesothelioma.

Authors:  Yue Xu; Ming Zheng; Robert E Merritt; Joseph B Shrager; Heather A Wakelee; Robert A Kratzke; Chuong D Hoang
Journal:  Chest       Date:  2013-11       Impact factor: 9.410

5.  Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth.

Authors:  Masaki Nasu; Michele Carbone; Giovanni Gaudino; Bevan H Ly; Pietro Bertino; David Shimizu; Paul Morris; Harvey I Pass; Haining Yang
Journal:  Genes Cancer       Date:  2011-05

6.  Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.

Authors:  Gerd R Silberhumer; Peter Brader; Joyce Wong; Inna S Serganova; Mithat Gönen; Segundo Jaime Gonzalez; Ronald Blasberg; Dmitriy Zamarin; Yuman Fong
Journal:  Mol Cancer Ther       Date:  2010-09-21       Impact factor: 6.261

Review 7.  Novel therapies in phase II and III trials for malignant pleural mesothelioma.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  J Natl Compr Canc Netw       Date:  2012-01       Impact factor: 11.908

Review 8.  Mesothelioma epidemiology, carcinogenesis, and pathogenesis.

Authors:  Haining Yang; Joseph R Testa; Michele Carbone
Journal:  Curr Treat Options Oncol       Date:  2008-08-15

9.  Spontaneous mesotheliomas in F344/N rats are characterized by dysregulation of cellular growth and immune function pathways.

Authors:  Pamela E Blackshear; Arun R Pandiri; Thai-Vu T Ton; Natasha P Clayton; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2013-08-26       Impact factor: 1.902

10.  Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.

Authors:  M Cioce; F Ganci; V Canu; A Sacconi; F Mori; C Canino; E Korita; B Casini; G Alessandrini; A Cambria; M A Carosi; R Blandino; V Panebianco; F Facciolo; P Visca; S Volinia; P Muti; S Strano; C M Croce; H I Pass; G Blandino
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.